Compare Intuit Inc. (INTU) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Mesoblast Limited — how do they compare? Intuit Inc. trades at $302.75 (market cap $81.21B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Intuit Inc. is far larger — about 46.4× Mesoblast Limited's market cap, and Intuit Inc. pays a 1.82% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and Mesoblast Limited for 15 Days on average.
| INTU | MESO | |
|---|---|---|
Market Cap | $81.21B | $1.75B |
Volume | 5,165,806 | 239,027 |
Sector | Technology | Health |
52-Week High | $683.39 | $20.96 |
52-Week Low | $255.07 | $13.19 |
Typical Hold Time | 66 Days | 15 Days |
Enterprise Value | $82.43B | $1.83B |
Dividend Yield | 1.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $303.88, up 2.23% today, with strong technical momentum as it approaches resistance near $307. The company demonstrates robust fundamentals with revenue growth from $18.83B in 2025 to projected $21.4B in 2026, net margins expanding to 21.29%, and consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $379.68 price target, though recent class action lawsuits create near-term sentiment headwinds.
INTU presents a compelling growth story with strong profitability and market leadership in financial software. The primary investment opportunity lies in continued QuickBooks and TurboTax monetization, while risks include legal overhang from securities litigation and competitive pressures in the fintech space. Current valuation at 18.46 P/E appears reasonable given earnings growth trajectory.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
